

1 **Title:** SARS-CoV-2 lethality decreased over time in two Italian Provinces.

2

3 **Authors:** Maria Elena Flacco<sup>1¶\*</sup>, Cecilia Acuti Martellucci<sup>2¶</sup>, Francesca Bravi<sup>3</sup>, Giustino Parruti<sup>4</sup>, Alfonso  
4 Mascitelli<sup>5</sup>, Lorenzo Mantovani<sup>6</sup>, Lamberto Manzoli<sup>1\*</sup>.

5

6 **Affiliations:**

7 <sup>1</sup> Department of Medical Sciences, University of Ferrara, Italy;

8 <sup>2</sup> Department of Biomedical Sciences and Public Health, University of the Marche Region, Ancona, Italy;

9 <sup>3</sup> "Sant'Anna" University Hospital of Ferrara, Italy;

10 <sup>4</sup> Local Health Authority of Pescara, Italy;

11 <sup>5</sup> Regional Healthcare Agency of Abruzzo, Pescara, Italy.

12 <sup>6</sup> School of Medicine and Surgery, University Bicocca, Milan, Italy.

13

14 **Short title:** SARS-CoV-2 lethality decrease over time.

15 **Key words:** SARS-CoV-2; COVID-19; Case-fatality rate; Mortality.

16 \* [lmanzoli@post.harvard.edu](mailto:lmanzoli@post.harvard.edu) (LM)

17 **Word count:** 1440.

18 **Number of Tables/Figures:** 3.

19

20 ¶ These authors equally contributed to this manuscript.

21

22 **Abbreviations:** COPD, chronic obstructive pulmonary disease; COVID-19, coronavirus disease 2019; CVD,  
23 cardiovascular disease; HR, hazard ratio; RT-PCR, reverse transcription polymerase chain reaction; SARS-  
24 CoV-2, severe acute respiratory syndrome coronavirus 2; SDO, hospital discharge abstract (scheda di  
25 dimissione ospedaliera).

26

27

## 28 **Abstract**

29

### 30 **Background**

31 Some experts recently reported that SARS-CoV-2 lethality decreased considerably, but no evidence is yet  
32 available. This retrospective cohort study aimed to evaluate whether SARS-CoV-2 case-fatality rate  
33 decreased with time, adjusting for main potential confounders.

### 34 **Methods and findings**

35 We included all SARS-CoV-2 infected subjects diagnosed in Ferrara and Pescara provinces, Italy.  
36 Information were collected from local registries, clinical charts, and electronic health records. We compared  
37 the case-fatality rate of the subjects diagnosed during April and March, 2020. We used Cox proportional  
38 hazards analysis and random-effect logistic regression, adjusting for age, gender, hypertension, type II  
39 diabetes, major cardiovascular diseases (CVD), chronic obstructive pulmonary diseases (COPD), cancer and  
40 renal disease. The sample included 1946 subjects (mean age 58.8y; 45.7% males). 177 persons deceased,  
41 after a mean of 11.7 days of follow-up. From March to April, the case-fatality rate significantly decreased in  
42 the total sample (10.8% versus 6.0%;  $p < 0.001$ ), and in any subgroup of patients. Large reductions of the  
43 lethality were observed among the elderly (from 30.0% to 13.4%), and subjects with hypertension (23.0% to  
44 12.1%), diabetes (30.3% to 8.4%), CVD (31.5% to 12.1%), COPD (29.7% to 11.4%), and renal disease  
45 (32.3% to 11.5%). In April, the adjusted hazard ratio of death was 0.42 (95% Confidence Interval: 0.29-  
46 0.60). The mean age of those who died substantially increased from March ( $77.9 \pm 10.8y$ ) to April  
47 ( $86.9 \pm 7.7y$ ).

### 48 **Conclusions**

49 In this sample, SARS-CoV-2 case-fatality rate decreased considerably over time, supporting recent claims of  
50 a substantial improvement of SARS-CoV-2 clinical management. The findings are inevitably preliminary  
51 and require confirmation.

52

53

54 **Author summary**

55

56 **Why was this study done?**

- 57 • Some experts recently reported that SARS-CoV-2 lethality decreased considerably, but no evidence  
58 is yet available.

59

60 **What did the researchers do and find?**

- 61 • We carried out a retrospective cohort study on 1946 SARS-CoV-2 infected subjects from two Italian  
62 provinces, evaluating the potential variation of the case-fatality rate over time.
- 63 • From March to April, in both univariate and multivariable analyses, SARS-CoV-2 case-fatality rate  
64 significantly and substantially decreased, overall and in any subgroup of subjects.

65

66 **What do these findings mean?**

- 67 • The therapies and clinical management of SARS-CoV-2 infected subjects might have substantially  
68 improved over time.

69

70

71

## 72 **Introduction**

73 As of May 18, 2020, SARS-CoV-2 pandemic has caused 320,000 deaths worldwide [1], with largely  
74 discrepant case-fatality rates across countries (from <1% to 16%) [2], likely due to differences in population  
75 age structure [3, 4], variations in testing policies and case recording [5], and/or preparedness of the  
76 healthcare system, which in turn is affected by the intensity of the spread [4, 5].

77 Since the start of the pandemic, Italy has been among the countries with the highest death toll, with more  
78 than 32,000 recorded deaths [1], and an estimated case-fatality rate of 14% [2], which peaked at 20% among  
79 the citizens aged  $\geq 80$  years [6].

80 In the last few weeks, some clinicians suggested that SARS-CoV-2 lethality decreased considerably, mostly  
81 as a consequence of more tailored therapeutic approaches [7-11]. Although the claims were made by expert  
82 physicians, actively engaged in the care of infected patients, the available evidence is anecdotal or based  
83 upon case-studies.

84 We analysed the data of all infected cases in two Italian Provinces to evaluate whether SARS-CoV-2 case-  
85 fatality rate decreased with time, adjusting for main potential confounders.

86

## 87 **Methods**

88 This retrospective cohort study included all subjects infected with SARS-CoV-2, diagnosed in the Provinces  
89 of Ferrara and Pescara, between March 3 (the onset date of the first cases), and April 25, 2020. All  
90 participants were followed up to May 5, 2020. All infections were diagnosed by the central laboratories of  
91 Ferrara University Hospital or Pescara Hospital through RT-PCR (Reverse transcription polymerase chain  
92 reaction) test on nasopharyngeal swabs, and were confirmed by the Italian National Institute of Health.  
93 Information on age, gender, and pre-existing conditions of all participants were collected from local  
94 registries, clinical charts (for hospitalized patients), and through data-linkage with hospital discharge  
95 abstracts (Italian SDO) and the National database of drug prescription. Electronic databases were queried  
96 from the day of the diagnosis until January 1st, 2015. All data have been revised manually by two physicians  
97 (LM and MEF), and the following conditions have been included in the analyses: hypertension, type II

98 diabetes, major cardiovascular diseases (heart failure, myocardial infarction and stroke - CVD), chronic  
99 obstructive pulmonary diseases (COPD, bronchitis, pneumonia, asthma, and emphysema), malignant tumors  
100 and renal disease.

101 The study complies with the Declaration of Helsinki, the research protocol was approved by the Ethics  
102 Committee of the Emilia-Romagna Region (code 287, approved on March 24, 2020), and the requirement for  
103 informed consent was waived because of the retrospective and pseudo-anonymized nature of the data.

104

## 105 **Data Analysis**

106 We compared the case-fatality rate (fatal / confirmed cases) during the first 29 days after the index day (from  
107 March 3 to March 31) with that of the second half of the period (days 30-53; from April 1 to April 25). The  
108 differences between the two periods were initially evaluated using t-test for continuous variables, and chi-  
109 squared test for categorical ones. The potential independent predictors of death were then evaluated using  
110 Cox proportional hazards analysis (using the data censored at May 5, to include  $\geq 10$  days of follow-up). All  
111 covariates were included a priori in the model in their original form, with the exception of age, which was  
112 treated as either continuous or ordinal, to explore the association between the outcome and several age  
113 classes. Schoenfeld's test was used to assess the validity of proportional hazards assumption, and Nelson-  
114 Aalen cumulative hazard estimates to check the validity of constant incidence ratios during the follow-up  
115 [12]. Using the data censored at 20 days of follow-up, a random-effect logistic regression was also fit, with  
116 province as the cluster unit. The same above criteria were used to build the final model. Missing data were  
117  $< 5\%$  in all primary analyses; therefore, no missing imputation technique was adopted. Statistical significance  
118 was defined as a two-sided  $p$ -value  $< 0.05$ , and all analyses were carried out using Stata, version 13.1 (Stata  
119 Corp., College Station, TX, 2014).

120

## 121 **Results**

122 The sample consisted of 1946 subjects (mean age 58.8y; 45.7% males); of them, 31.2% were hypertensive,  
123 12.3% diabetics, and 16.6% with CVD. Some of the characteristics of the sample significantly varied from  
124 March to April. Infected subjects were older by 5.6 years, and the proportion of females, diabetics, subjects  
125 with CVD and renal diseases significantly increased (Table 1).

126

127 **Table 1. Characteristics of the sample, overall and by time of SARS-CoV-2 infection**  
 128 **diagnosis after the first case (March 3, 2020).**

|                                  | Total sample<br>(n=1946) | March 2020 <sup>a</sup><br>(n=1244) | April 2020 <sup>b</sup><br>(n=702) | p*     |
|----------------------------------|--------------------------|-------------------------------------|------------------------------------|--------|
| Mean age (SD), years             | 58.8 (21.3)              | 56.8 (20.0)                         | 62.4 (23.0)                        | <0.001 |
| Age-class in years, %            |                          |                                     |                                    |        |
| - <18                            | 3.5                      | 3.9                                 | 2.8                                | 0.2    |
| - 18-39.9                        | 14.8                     | 14.7                                | 15.0                               | 0.9    |
| - 40-49.9                        | 15.0                     | 16.6                                | 12.1                               | 0.008  |
| - 50-59.9                        | 19.0                     | 20.1                                | 17.0                               | 0.09   |
| - 60-69.9                        | 13.8                     | 16.1                                | 9.7                                | <0.001 |
| - 70-79.9                        | 13.2                     | 14.1                                | 11.7                               | 0.13   |
| - ≥80                            | 20.8                     | 14.6                                | 31.8                               | <0.001 |
| Male gender, %                   | 45.7                     | 50.2                                | 37.9                               | <0.001 |
| Hypertension, %                  | 31.2                     | 32.9                                | 28.4                               | 0.038  |
| Diabetes, %                      | 12.3                     | 10.6                                | 15.2                               | 0.003  |
| Major cardiovascular diseases, % | 16.6                     | 14.6                                | 20.1                               | 0.002  |
| COPD, %                          | 5.6                      | 6.0                                 | 5.0                                | 0.4    |
| Cancer, %                        | 7.7                      | 8.3                                 | 6.6                                | 0.2    |
| Renal diseases, %                | 5.9                      | 5.0                                 | 7.4                                | 0.029  |

129

130 <sup>a</sup> From March 3 to March 31.

131 <sup>b</sup> From April 1 to April 25.

132 \* Chi-squared test for categorical variables, t-test for continuous ones.

133

134 Overall, 177 persons deceased (after a mean of 11.7 days of follow-up): 135 of the 1244 subjects diagnosed  
 135 in March, 42 of the 702 subjects diagnosed in April. The mean age of those who died substantially increased:  
 136 it was 77.9±10.8 for those diagnosed in March, 86.9±7.7 for those detected in April (p<0.001). In March, 28  
 137 of those deceased were younger than 70 years, and 8 were younger than 60 years. In April, a single death  
 138 occurred in subjects younger than 70 years.

139 From March to April, the overall case-fatality rate significantly decreased (10.8% versus 6.0%, respectively;  
 140 p<0.001 - Fig 1).

141

142 **Figure 1. SARS-CoV-2 case-fatality rate in the first two months of the pandemic (March and April,**  
 143 **2020), overall and stratified for the most frequent risk classes (all  $p < 0.05$ ). Vertical bars are referred**  
 144 **to 95% confidence intervals.**

145

146 As shown in Table 2, a reduction of SARS-CoV-2 lethality was observed in any age-class and any category  
 147 of risk. The decrease was however larger among the subjects at higher risk of death: with the lethality  
 148 dropping from 23.4% to 6.1% in the age-class 70-79y, and from 36.3% to 16.1% among the elderly (80+  
 149 years); both  $p < 0.05$ . Similar reductions of the case-fatality rate were observed among the subjects with  
 150 hypertension (from 23.0% to 12.1%), diabetes (from 30.3% to 8.4%), CVD (from 31.5% to 12.1%), COPD  
 151 (from 29.7% to 11.4%), and renal disease (from 32.3% to 11.5%; all univariate  $p$ -values  $< 0.05$ ).

152

153 **Table 2. Proportion of deaths, overall and by time of SARS-CoV-2 infection diagnosis after**  
 154 **the first case (March 3, 2020), and hazard ratios (HRs) predicting the time to death of patients**  
 155 **diagnosed in April vs March 2020.**

|                                  | Total sample | March 2020 <sup>a</sup> | April 2020 <sup>b</sup> | P <sup>c</sup> | April vs March HR (95% CI) | P <sup>d</sup> |
|----------------------------------|--------------|-------------------------|-------------------------|----------------|----------------------------|----------------|
| Overall                          | 9.1          | 10.8                    | 6.0                     | <0.001         | 0.42 (0.29-0.60)           | <0.001         |
| Age-class in years, %            |              |                         |                         |                |                            |                |
| - <18                            | 0.0          | 0.0                     | 0.0                     | --             | --                         | --             |
| - 18-39.9                        | 0.0          | 0.0                     | 0.0                     | --             | --                         | --             |
| - 40-49.9                        | 0.7          | 1.0                     | 0.0                     | 0.4            | --                         | --             |
| - 50-59.9                        | 1.9          | 2.4                     | 0.8                     | 0.3            | 0.37 (0.04-3.32)           | 0.4            |
| - 60-69.9                        | 7.5          | 10.0                    | 0.0                     | 0.007          | --                         | --             |
| - 70-79.9                        | 17.9         | 23.4                    | 6.1                     | 0.001          | 0.31 (0.12-0.79)           | 0.014          |
| - ≥80                            | 25.2         | 36.3                    | 16.1                    | <0.001         | 0.51 (0.33-0.77)           | 0.002          |
| Gender, %                        |              |                         |                         |                |                            |                |
| - Females                        | 8.0          | 9.0                     | 6.4                     | 0.12           | 0.43 (0.27-0.69)           | <0.001         |
| - Males                          | 10.4         | 12.7                    | 5.3                     | 0.001          | 0.35 (0.19-0.62)           | <0.001         |
| Hypertension, %                  |              |                         |                         |                |                            |                |
| - No                             | 4.4          | 4.9                     | 3.6                     | 0.3            | 0.43 (0.24-0.78)           | 0.005          |
| - Yes                            | 19.4         | 23.0                    | 12.1                    | 0.001          | 0.45 (0.28-0.72)           | 0.001          |
| Diabetes, %                      |              |                         |                         |                |                            |                |
| - No                             | 7.5          | 8.5                     | 5.6                     | 0.025          | 0.44 (0.29-0.68)           | <0.001         |
| - Yes                            | 20.5         | 30.3                    | 8.4                     | <0.001         | 0.36 (0.17-0.76)           | 0.007          |
| Major cardiovascular diseases, % |              |                         |                         |                |                            |                |
| - No                             | 6.3          | 7.3                     | 4.5                     | 0.023          | 0.49 (0.30-0.79)           | 0.003          |
| - Yes                            | 23.0         | 31.5                    | 12.1                    | <0.001         | 0.37 (0.21-0.66)           | 0.001          |
| COPD, %                          |              |                         |                         |                |                            |                |
| - No                             | 8.2          | 9.7                     | 5.7                     | 0.003          | 0.49 (0.33-0.72)           | <0.001         |
| - Yes                            | 23.9         | 29.7                    | 11.4                    | 0.036          | 0.26 (0.08-0.82)           | 0.022          |

---

|                   |      |      |      |       |                  |        |
|-------------------|------|------|------|-------|------------------|--------|
| Cancer, %         |      |      |      |       |                  |        |
| - No              | 8.2  | 9.8  | 5.5  | 0.001 | 0.43 (0.29-0.64) | <0.001 |
| - Yes             | 19.5 | 22.3 | 13.0 | 0.2   | 0.47 (0.19-1.18) | 0.11   |
| Renal diseases, % |      |      |      |       |                  |        |
| - No              | 8.2  | 9.7  | 5.5  | 0.002 | 0.48 (0.32-0.72) | <0.001 |
| - Yes             | 22.8 | 32.3 | 11.5 | 0.009 | 0.20 (0.07-0.54) | 0.002  |

---

156

157 <sup>a</sup> From March 3 to March 31.

158 <sup>b</sup> From April 1 to April 25.

159 <sup>c</sup> Chi-squared test for categorical variables, t-test for continuous ones.

160 <sup>d</sup> Cox proportional hazard model, adjusted for age, gender, hypertension, diabetes, major cardiovascular  
161 diseases, COPD, cancer and renal disease. Some models could not be fit due to the scarce number of deaths.

162

163 Cox analysis substantially confirmed univariate results: adjusting for age, gender, hypertension, diabetes,  
164 CVD, COPD, cancer and renal disease, the hazard ratio (HR) of death of those diagnosed in April, as  
165 compared to March, was 0.42 (95% Confidence Interval - CI: 0.29-0.60 - Table 2). With the only exception  
166 of the subjects with history of cancer, a significantly, considerably lower likelihood of death was observed in  
167 any subset of the sample, with HRs ranging from 0.20 among the subjects with renal disease, up to 0.51  
168 among those aged 80 years or more (Table 2). The results of the random-effect logistic regression did not  
169 vary: overall, the adjusted odds ratio of death at 20 days was 0.29 (95% CI: 0.19-0.45;  $p < 0.001$ ) for those  
170 diagnosed in April, as compared to the subjects detected in March.

171

## 172 **Discussion**

173 This study provides the first evidence of a considerable decrease of SARS-CoV-2 case-fatality rate over  
174 time. From March to April 2020, the death rate decreased by more than 50% in all age-classes, being larger  
175 among the subjects with the highest risk of death because of comorbidities [13, 14]. This finding was  
176 confirmed in all multivariable analyses, adjusting for several potential confounders.

177 It is complex to discern which could be the potential reasons for the observed, entirely novel findings. The  
178 first, most obvious explanation, is that the healthcare system might have been overcrowded during the  
179 epidemic peak in March, with a loss of efficacy [15]. This is however very unlikely to apply to the present  
180 sample, because SARS-CoV-2 infection rates were relatively low - and never exceeded the capacity of the  
181 intensive care units - in the two provinces under analysis [16].

182 Other potential, non mutually exclusive explanations include virus mutation and substantial improvements in  
183 the organization (including the expansion of dedicated hospital beds), therapy and management of the  
184 infected subjects. Some scientists suggested that a less virulent viral strain, with consequent reduced  
185 lethality, might emerge during the pandemic [10]. Alternatively, the infection might have accelerated the  
186 clinical path of the most fragile individuals in the earlier phases. Both hypotheses, however, are currently  
187 unsubstantiated by data [17]. Concerning the therapy, a growing number of clinicians suggest that the current  
188 therapeutic approach, based upon the early administration of more tailored medications, is considerably  
189 improving the clinical course of COVID-19 [7-9, 11]. In the two provinces under investigation, the treatment  
190 is currently based upon antiviral agents (lopinavir / ritonavir), intensive respiratory support [18, 19], and,  
191 from the latest days of March, low molecular weight heparin and monoclonal antibodies against  
192 inflammatory cytokines (e.g. tocilizumab), which showed some preliminary, promising results [18, 20-23].  
193 Given that available data are anecdotal, and no therapeutics is currently recommended for or against SARS-  
194 CoV-2 infection or disease [24], only the results of the several randomized trials that are being conducted on  
195 the above treatments [18, 25], will permit to discern which approach, and to what extent, contributed to the  
196 improvement of SARS-CoV-2 infection prognosis.

197 The main limitations of the study are the inclusion of only two provinces from a single country, and the lack  
198 of data on body mass index, which is emerging as significant predictor of death from COVID-19 [26, 27].

199 In conclusion, the present study provided evidence of a significant, considerable decrease of SARS-CoV-2  
200 case-fatality rate between March and April, 2020, supporting preliminary claims on a substantial  
201 improvement of the therapeutic approaches. The findings are inevitably preliminary and require confirmation  
202 from further datasets and ongoing randomized trials.

203

204

205 **Acknowledgments**

206 The authors are grateful to Dr. Giorgia Valpiani and Dr. Nicola Napoli for their valuable help in data  
207 collection.

208

209 **Financial disclosure statement:** This work was not funded.

210

211 **Competing interests:** All authors declare that they have no potential conflict of interest.

212

213

214

## 215 **References**

216

- 217 1. COVID-19 Coronavirus Outbreak [Internet]. Dadax. 2020 [cited March 14, 2020]. Available from:  
218 <https://www.worldometers.info/coronavirus/>.
- 219 2. Johns Hopkins University & Medicine. Coronavirus Resource Center - Mortality Analyses 2020  
220 [May 16, 2020]. Available from: <https://coronavirus.jhu.edu/data/mortality>.
- 221 3. Dowd JB, Andriano L, Brazel DM, Rotondi V, Block P, Ding X, et al. Demographic science aids in  
222 understanding the spread and fatality rates of COVID-19. *Proc Natl Acad Sci U S A*. 2020;117(18):9696-8.  
223 Epub 2020/04/18. doi: 10.1073/pnas.2004911117  
224 2004911117 [pii]. PubMed PMID: 32300018.
- 225 4. Boccia S, Ricciardi W, Ioannidis JPA. What Other Countries Can Learn From Italy During the  
226 COVID-19 Pandemic. *JAMA internal medicine*. 2020. Epub 2020/04/08. doi:  
227 10.1001/jamainternmed.2020.1447. PubMed PMID: 32259190.
- 228 5. Iosa M, Paolucci S, Morone G. Covid-19: A Dynamic Analysis of Fatality Risk in Italy. *Front Med*.  
229 2020;7:185. doi: 10.3389/fmed.2020.00185.
- 230 6. Onder G, Rezza G, Brusaferro S. Case-Fatality Rate and Characteristics of Patients Dying in  
231 Relation to COVID-19 in Italy. *JAMA*. 2020. Epub 2020/03/24. doi: 10.1001/jama.2020.4683  
232 2763667 [pii]. PubMed PMID: 32203977.
- 233 7. Furuya K, Kato K, Nagata I, Makimura N. [Studies on the blood constituents of the neonates  
234 delivered by the induced delivery of the Defense Medical College method]. *Nihon Sanka Fujinka Gakkai*  
235 *Zasshi*. 1986;38(2):215-22. Epub 1986/02/01. PubMed PMID: 3457089.
- 236 8. Sano M, Sakagami M, Harada T, Matsunaga T, Tominaga Y, Nakayama M. Histopathology of the  
237 temporal bones in thanatophoric dysplasia. *Med J Osaka Univ*. 1991;40(1-4):51-7. Epub 1991/03/01.  
238 PubMed PMID: 1369657.
- 239 9. Scientists disagree: the virus is losing its virulence, but it is forbidden to say it [Quella faida tra  
240 scienziati sul virus: è indebolito ma è vietato dirlo]. *Il Giornale*. May 11, 2020.

- 241 10. Tang X, Wu C, Li X, Song Y, Yao X, Wu X, et al. On the Origin and Continuing Evolution of  
242 SARS-CoV-2. *National Science Review*. 2020;nwaa036. doi: <https://doi.org/10.1093/nsr/nwaa036>.
- 243 11. Di Giambenedetto S, Ciccullo A, Borghetti A, Gambassi G, Landi F, Visconti E, et al. Off-label Use  
244 of Tocilizumab in Patients with SARS-CoV-2 Infection. *Journal of medical virology*. 2020. Epub  
245 2020/04/17. doi: 10.1002/jmv.25897. PubMed PMID: 32297987.
- 246 12. Manzoli L, La Vecchia C, Flacco ME, Capasso L, Simonetti V, Boccia S, et al. Multicentric cohort  
247 study on the long-term efficacy and safety of electronic cigarettes: study design and methodology. *BMC*  
248 *Public Health*. 2013;13:883. Epub 2013/09/26. doi: 10.1186/1471-2458-13-883  
249 1471-2458-13-883 [pii]. PubMed PMID: 24063569; PubMed Central PMCID: PMC3853622.
- 250 13. Williamson E, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. OpenSAFELY: factors  
251 associated with COVID-19-related hospital death in the linked electronic health records of 17 million adult  
252 NHS patients [submitted]. *MedRxiv*. 2020. Epub May 7, 2020. doi:  
253 <https://doi.org/10.1101/2020.05.06.20092999>.
- 254 14. Mehra MR, Desai SS, Kuy S, Henry TD, Patel AN. Cardiovascular Disease, Drug Therapy, and  
255 Mortality in Covid-19. *N Engl J Med*. 2020. Epub 2020/05/02. doi: 10.1056/NEJMoa2007621. PubMed  
256 PMID: 32356626.
- 257 15. Phua J, Weng L, Ling L, Egi M, Lim CM, Divatia JV, et al. Intensive care management of  
258 coronavirus disease 2019 (COVID-19): challenges and recommendations. *Lancet Respir Med*.  
259 2020;8(5):506-17. Epub 2020/04/10. doi: S2213-2600(20)30161-2 [pii]  
260 10.1016/S2213-2600(20)30161-2. PubMed PMID: 32272080; PubMed Central PMCID: PMC7198848.
- 261 16. ProtezioneCivile. COVID-19 Italia - Monitoraggio della situazione 2020 [April 6, 2020]. Available  
262 from:  
263 <http://opendatadpc.maps.arcgis.com/apps/opsdashboard/index.html#/b0c68bce2cce478eaac82fe38d4138b1>.
- 264 17. MacLean O, Orton RJ, Singer JB, Robertson D. No evidence for distinct types in the evolution of  
265 SARS-CoV-2. *Virus Evolution*. 2020;6(1):veaa034. doi: 10.1093/ve/veaa034.
- 266 18. Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic Treatments for Coronavirus  
267 Disease 2019 (COVID-19): A Review. *JAMA*. 2020. Epub 2020/04/14. doi: 10.1001/jama.2020.6019  
268 2764727 [pii]. PubMed PMID: 32282022.


- 269 19. Bhimraj A, Morgan RL, Shumaker AH, Lavergne V, Baden L, Cheng VC, et al. Infectious Diseases  
270 Society of America Guidelines on the Treatment and Management of Patients with COVID-19. *Clinical*  
271 *infectious diseases : an official publication of the Infectious Diseases Society of America*. 2020. Epub  
272 2020/04/28. doi: 10.1093/cid/ciaa478. PubMed PMID: 32338708; PubMed Central PMCID: PMC7197612.
- 273 20. Capra R, De Rossi N, Mattioli F, Romanelli G, Scarpazza C, Sormani MP, et al. Impact of low dose  
274 tocilizumab on mortality rate in patients with COVID-19 related pneumonia. *Eur J Intern Med*. 2020. Epub  
275 2020/05/15. doi: 10.1016/j.ejim.2020.05.009  
276 S0953-6205(20)30194-1 [pii]. PubMed PMID: 32405160; PubMed Central PMCID: PMC7219361.
- 277 21. Mazzitelli M, Arrighi E, Serapide F, Pelle MC, Tassone B, Lionello R, et al. Use of subcutaneous  
278 tocilizumab in patients with COVID-19 pneumonia. *J Med Virol*. 2020. Epub 2020/05/16. doi:  
279 10.1002/jmv.26016. PubMed PMID: 32410234.
- 280 22. AIFA. LMWH in adult COVID-19 patients [Eparine a basso peso molecolare nei pazienti adulti con  
281 COVID-19]. In: Italian, Medicines, Agency, editors. Rome2020.
- 282 23. American Society of H. COVID-19 and VTE/Anticoagulation. 2020 May 18, 2020. Report No.
- 283 24. CDC CfDCaP. Information for Clinicians on Investigational Therapeutics for Patients with COVID-  
284 19: CDC; 2020. Available from: <https://www.cdc.gov/coronavirus/2019-ncov/hcp/therapeutic-options.html>.
- 285 25. World Health Organization. Data visualizations and mapping of registered studies for COVID-19  
286 experimental treatments. 2020.
- 287 26. Simonnet A, Chetboun M, Poissy J, Raverdy V, Noulette J, Duhamel A, et al. High prevalence of  
288 obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical  
289 ventilation. *Obesity (Silver Spring)*. 2020. Epub 2020/04/10. doi: 10.1002/oby.22831. PubMed PMID:  
290 32271993.
- 291 27. Lighter J, Phillips M, Hochman S, Sterling S, Johnson D, Francois F, et al. Obesity in patients  
292 younger than 60 years is a risk factor for Covid-19 hospital admission. *Clinical infectious diseases : an*  
293 *official publication of the Infectious Diseases Society of America*. 2020. Epub 2020/04/10. doi:  
294 10.1093/cid/ciaa415. PubMed PMID: 32271368; PubMed Central PMCID: PMC7184372.

295  
296  
297

298

299 **Figure 1.**

300



301  
302